The most recent listing of current clinical trials for breast cancer appears below. Should you be interested in learning more about any of these clinical trials, please use our Contact Us form.
Site: Breast
| Protocol ID |
|
Title |
|
| Industry-breast |
|
A Prospective, Randomized, Double-Blind, Stratified, Placebo-Controlled, Multi-Center, 3-Arm Trial of the Continued Efficacy and Safety of Zometa® (Every 4 weeks vs. Every 12 weeks vs. Placebo) in Patients with Documented Bone Metastases From Breast Cancer
Keywords: bone metastases from breast cancer |
|
| ACOSOG Z1031 |
|
A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg) or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer
Keywords: postmenopausal women with state II or III estrogen receptor positive breast cancer |
|
| NSABP B-36 |
|
A Clinical Trial of Adjuvant Therapy Comparing 6 Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to 4 Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-Negative Breast Cancer
Keywords: chemotherapy, lymph node negative breast cancer |
|
| RTOG/NSABP 0413 |
|
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Keywords: whole breast irradiation or partial breast irradiation, stage 0, I, or II breast cancer |
|
| NSABP B-42 |
|
A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Post-Menopausal Women with Hormone Receptor Positive Breast Cancer
Keywords: post-menopausal women with hormone receptor positive breast cancer |
|
| TAILORx |
|
PACCT-1: Program for the Assessment of Clinical Cancer Tests, a Trial Assigning IndividuaLized Options for Treatment (TAILORx)".
Keywords: individualized options for treatment |
|
| NCIC CTG MAP3 |
|
A Phase III Randomized Study of Exemestane vs Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer
Keywords: postmenopausal women at increased risk of developing breast cancer |